In this episode, Dr. Justin Lee joins Dr. Christopher Beck to discuss hepatocellular carcinoma (HCC) and interventional oncology in private practice. Dr. Lee tells us how he frames his HCC patients and works with medical oncologists for treatment plans and procedures. We talk about the importance of IR bringing cases to the tumor board, the evolution of cases involving ablation, and why Dr. Lee started moving towards radioembolization (Y90). We review how to approach HCC cases while working with medical oncologists. We examine the differences between using resin and glass for radioembolization and when they should be used. Dr. Lee shares why IR should start looking into arterial drug delivery for immunotherapies. RESOURCES MENTIONED: NEJM: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma https://www.nejm.org/doi/10.1056/NEJMoa1915745 This paper, mentioned by Dr. Lee, discusses the third phase of an HCC trial.
BackTable Vascular & Interventional